Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)

Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were randomized at hospital discharge to receive r...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo de Oliveira, André Luiz Malavasi, de Oliveira Pereira, Renata Fernanda, Agati, Leandro Barile, Ribeiro, Camilla Moreira, Kawamura Suguiura, Gabrielly Yukimi, Cioni, Claudia Helena, Bermudez, Marilsa, Pirani, Márcia Bermudez, Caffaro, Roberto Augusto, Castelli, Valter, Resende Aguiar, Valéria Cristina, Volpiani, Giuliano Giova, Paschoa, Adilson, Scarlatelli Macedo, Ariane Vieira, de Barros e Silva, Pedro Gabriel Melo, de Campos Guerra, João Carlos, Fareed, Jawed, Lopes, Renato Delascio, Ramacciotti, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732794/
https://www.ncbi.nlm.nih.gov/pubmed/36474344
http://dx.doi.org/10.1177/10760296221132556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732794/
https://www.ncbi.nlm.nih.gov/pubmed/36474344
http://dx.doi.org/10.1177/10760296221132556

Ejemplares similares